Focus on Antibody Discovery and Optimization
100% efficiency of multiple point mutations Over 10e10 diversity in single library construction Construct a 10e10 diversity fully synthetic library in 2 weeks Construct a 10e13 diversity fully synthetic library in 3 monthsMore
Natural drug library technology based on phage display Fully synthetic library technology for macromolecular drugs High throughput screening technology for screening high affinity drugsMore
The next-generation BCMACAR-T, a self-developed CAR-T drug targeting chemokine receptor, has entered Phase I clinical trials with enhanced tumor targeting capability. It is able to effectively clear tumors with just 1/10 of the conventional CAR-T cell dosage.More
Underlying tools of AI that represent the advanced level of the industry Massive real self-owned data for reliability verification Whole-process micro-innovation targeting traditional pain points Shorter cycles, higher success ratesMore
商业模式
Construction of macromolecular drug libraries HIT screening Lead optimizationMore
Cross-blood brain barrier shuttle antibody technology Bidirectional transmucosal system shuttle antibody technology Antibody protac technology Enduring effect technology for protein/multi-pulse drugsMore
CAR-T drugs Antibody-radionuclide conjugates Droplet-based microfluidics and functional antibody development platform AI algorithms and "drug creators" version 1.0More
PROJECT CASES
We have been working hard for a better tomorrow.
Compared with conventional antibodies, nanobodies possess many unique advantages in expression and purification, stability, immunogenicity, and...
In recent years, with the launch of various antibody drugs, research on antibodies has become a hot topic in the biopharmaceutical field. Antibody...
Chimeric Antigen Receptor T-Cell Immunotherapy (CAR-T therapy) is an emerging cell-targeted therapy for treating tumors. It involves engineering T cells...
